Seattle Genetics, Inc. (NASDAQ:SGEN) Rating Changes as of May 17, 2018

May 17, 2018 - By William Cox

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
Big Money Sentiment increased to 1.23 in Q4 2017. It has change of 0.45, from 2017Q3’s 0.78. The ratio is positive due to Seattle Genetics, Inc. positioning: 24 sold and 67 reduced. 44 funds took positions and 68 increased positions. Investors holded 140.23 million in 2017Q3 but now own 141.83 million shares or 1.14% more.
Pictet Asset Limited holds 0.16% or 1.18 million shs in its capital. British Columbia Inv Mngmt Corp reported 27,525 shs stake. Ubs Asset Mngmt Americas Inc invested in 726,083 shs. Commerzbank Aktiengesellschaft Fi accumulated 50,037 shs or 0.03% of the stock. 108,000 were reported by Spark Mgmt Ltd Liability Co. Asset Incorporated holds 4,346 shs or 0.01% of its capital. Regions Fincl holds 1,400 shs or 0% of its capital. Morgan Stanley holds 0% or 177,696 shs. Trexquant Inv L P reported 17,397 shs. The Alabama-based Fjarde Ap has invested 0.03% in Seattle Genetics, Inc. (NASDAQ:SGEN). Primecap Management Ca holds 12.71 million shs. Alpha Windward Limited Liability Corp holds 0.01% or 284 shs. Prudential Financial Inc holds 6,091 shs or 0% of its capital. Parametric Port Llc accumulated 104,579 shs. Fmr Lc stated it has 6.43 million shs.

Seattle Genetics, Inc. registered $268.25 million net activity with 3 insider buys and 10 insider sales since December 11, 2017. On Thursday, May 3 Shares for $215,238 were sold by Cline Darren S. Shares for $290,604 were sold by HIMES VAUGHN B on Thursday, March 15. On Friday, March 9 SIEGALL CLAY B sold $1.08M worth of Seattle Genetics, Inc. (NASDAQ:SGEN). DRACHMAN JONATHAN G also sold $552,452 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, March 5.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

In total 8 analysts cover Seattle Genetics (NASDAQ:SGEN). “Buy” rating has 6, “Sell” are 0, while 2 are “Hold”. 75% are bullish. 11 are the (NASDAQ:SGEN)’s analyst reports since January 31, 2018 according to StockzIntelligence Inc. On Wednesday, February 14 the rating was upgraded by JP Morgan to “Overweight”. In Wednesday, February 14 report J.P. Morgan upgraded it to “Buy” rating and $66.0 target. On Friday, April 27 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, February 7 the company was maintained by Needham. On Wednesday, February 7 the firm earned “Buy” rating by H.C. Wainwright. The company rating was maintained by H.C. Wainwright on Thursday, February 1. In Tuesday, March 20 report RBC Capital Markets maintained the stock with “Buy” rating. On Wednesday, January 31 the firm has “Buy” rating given by RBC Capital Markets. The company rating was maintained by SunTrust on Wednesday, February 7. On Wednesday, February 7 Bank of America maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating. Bank of America has “Neutral” rating and $68 target. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain

Ticker’s shares touched $57.33 during the last trading session after 2.00% change.Seattle Genetics, Inc. has volume of 910,426 shares. Since May 17, 2017 SGEN has declined 20.48% and is downtrending. The stock underperformed the S&P 500 by 32.03%.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is valued at $9.07 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Currently it has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

For more Seattle Genetics, Inc. (NASDAQ:SGEN) news published briefly go to: Businesswire.com, Nasdaq.com, Seekingalpha.com, Businesswire.com or Streetinsider.com. The titles are as follows: “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” published on May 17, 2018, “Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags …” on May 09, 2018, “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” with a publish date: April 27, 2018, “Seattle Genetics Appoints Roger D. Dansey, MD, Chief Medical Officer” and the last “Seattle Genetics (SGEN) Announces Data Presentations at ASCO” with publication date: May 17, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.